PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns

PHASE3CompletedINTERVENTIONAL
Enrollment

313

Participants

Timeline

Start Date

May 14, 2016

Primary Completion Date

November 30, 2023

Study Completion Date

April 30, 2024

Conditions
Hypoxic-Ischemic Encephalopathy
Interventions
DRUG

Epoetin Alfa

DRUG

Normal saline

Trial Locations (24)

1023

Auckland City Hospital, Auckland

2031

Royal Hospital for Women, Randwick

2050

Royal Prince Alfred Hospital, Camperdown

2065

Royal North Shore Hospital, St Leonards

2104

Middlemore Hospital, Auckland

2145

Westmead Hospital, Westmead

2305

John Hunter Hospital, New Lambton

2605

Canberra Hospital, Garran

2747

Nepean Hospital, Kingswood

3052

The Royal Children's Hospital, Parkville

The Royal Women's Hospital, Parkville

3084

Mercy Hospital for Women, Heidelberg

3168

Monash Medical Centre, Clayton

3204

Waikato Hospital, Hamilton

4006

Royal Women's & Brisbane Hospital, Herston

4101

Mater Mothers' Hospital, South Brisbane

5006

Women's and Children's Hospital, North Adelaide

5042

Flinders Medical Centre, Bedford Park

6008

King Edward Memorial Hospital, Subiaco

Princess Margaret Hospital, Subiaco

6021

Wellington Hospital, Wellington

7000

Royal Hobart Hospital, Hobart

8140

Christchurch Hospital, Christchurch

229899

KK Women's and Children's Hospital, Singapore

All Listed Sponsors
collaborator

National Health and Medical Research Council, Australia

OTHER

lead

University of Sydney

OTHER

NCT03079167 - PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns | Biotech Hunter | Biotech Hunter